Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J MONTERO

Showing results (521-530 of 552) with videos related to

Pageof 56
Sort By:
NPJ Breast Cancer|May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter studyLinda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
The Journal of Clinical Endocrinology and Metabolism|November 28, 2020
Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate CancerJuan M Jiménez-Vacas, Vicente Herrero-Aguayo, Antonio J Montero-Hidalgo, et al.
JCO Precision Oncology|April 9, 2026
Prognostic Value of MammaPrint in Diverse Populations: Evaluating Racial Disparities in Breast Cancer OutcomesReine Abou Zeidane, Samuel Lichtman-Mikol, Courtney Pisano, et al.
JNCI Cancer Spectrum|February 8, 2023
Allostatic load and cardiovascular outcomes in males with prostate cancerNickolas Stabellini, Jennifer Cullen, Marcio S Bittencourt, et al.
JNCI Cancer Spectrum|August 8, 2024
Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort studyPriyanshu Nain, Nickolas Stabellini, Omar M Makram, et al.
Journal of Clinical Medicine|November 27, 2019
Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate CancerJuan M Jiménez-Vacas, Enrique Gómez-Gómez, Antonio J Montero-Hidalgo, et al.
Oncogene|August 9, 2018
Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanismsL Francisco Lorenzo-Martín, Carmen Citterio, Mauricio Menacho-Márquez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer StudyMiguel Martín, Elgene Lim, Mariana Chavez-MacGregor, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|September 11, 2022
Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genesJuan M Jiménez-Vacas, Antonio J Montero-Hidalgo, Enrique Gómez-Gómez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Pageof 56

Showing results (521-530 of 552) with videos related to

Sort By:
Pageof 56
NPJ Breast Cancer|May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter studyLinda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
The Journal of Clinical Endocrinology and Metabolism|November 28, 2020
Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate CancerJuan M Jiménez-Vacas, Vicente Herrero-Aguayo, Antonio J Montero-Hidalgo, et al.
JCO Precision Oncology|April 9, 2026
Prognostic Value of MammaPrint in Diverse Populations: Evaluating Racial Disparities in Breast Cancer OutcomesReine Abou Zeidane, Samuel Lichtman-Mikol, Courtney Pisano, et al.
JNCI Cancer Spectrum|February 8, 2023
Allostatic load and cardiovascular outcomes in males with prostate cancerNickolas Stabellini, Jennifer Cullen, Marcio S Bittencourt, et al.
JNCI Cancer Spectrum|August 8, 2024
Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort studyPriyanshu Nain, Nickolas Stabellini, Omar M Makram, et al.
Journal of Clinical Medicine|November 27, 2019
Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate CancerJuan M Jiménez-Vacas, Enrique Gómez-Gómez, Antonio J Montero-Hidalgo, et al.
Oncogene|August 9, 2018
Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanismsL Francisco Lorenzo-Martín, Carmen Citterio, Mauricio Menacho-Márquez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer StudyMiguel Martín, Elgene Lim, Mariana Chavez-MacGregor, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|September 11, 2022
Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genesJuan M Jiménez-Vacas, Antonio J Montero-Hidalgo, Enrique Gómez-Gómez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Pageof 56